First-line cisplatin + S-1 +/- nimotuzumab in patients with advanced gastric cancer

Trial Profile

First-line cisplatin + S-1 +/- nimotuzumab in patients with advanced gastric cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin; Gimeracil/oteracil/tegafur
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2012 Interim results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 22 Jun 2011 New trial record
    • 07 Jun 2011 Interim results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top